Covishield | Page 3 | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
May 16, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, MAY 16, 2025

Covishield

A healthcare worker prepares to administer a dose of the Oxford University-AstraZeneca vaccine, marketed by the Serum Institute of India (SII) as COVISHIELD, against the coronavirus disease (COVID-19), in Santiago, Dominican Republic February 17, 2021. REUTERS/Ricardo Rojas/File Photo
Coronavirus chronicle

India revises 2nd dose interval for Covishield to 4-8 weeks

"Keeping the existing scientific evidence in view, it appears that protection is enhanced if the second dose of Covishield is administered between 6-8 weeks, but not later than stipulated...

A healthcare worker prepares to administer a dose of the Oxford University-AstraZeneca vaccine, marketed by the Serum Institute of India (SII) as COVISHIELD, against the coronavirus disease (COVID-19), in Santiago, Dominican Republic February 17, 2021. REUTERS/Ricardo Rojas/File Photo
Coronavirus chronicle

India has supplied about 60 million Covid-19 vaccine doses to other countries

There was also a mock drill of conducting vaccination and reporting and review meetings at the block, district and state levels. Picture: Hindustan Times
Coronavirus chronicle

No clotting case in India after Oxford dose

A health department employee counts vials of the vaccine developed by Oxford/AstraZeneca as she prepares to pack them up before they are transported from the state storage to a regional one, during the coronavirus disease (Covid-19) pandemic, in Bhubaneswar, India, January 13, 2021. REUTERS/Danish Siddiqui
Coronavirus chronicle

Serum India’s Covishield part of Pakistan’s Covid-jab drive under vaccine alliance

A medical worker receives the AstraZeneca's Covishield coronavirus disease (Covid-19) vaccine in Yangon, Myanmar, after the country received 1.5 million doses of the vaccine manufactured by the Serum Institute of India, January 27, 2021. REUTERS/Shwe Paw Mya Tin
Coronavirus chronicle

Myanmar launches vaccination drive, prioritises frontline healthcare workers

Workers pack syringes at the Hindustan Syringes factory in Faridabad, India on Sept. 2, 2020. SAJJAD HUSSAIN/AFP/GETTY IMAGES
Analysis

India’s vaccine diplomacy

FILE PHOTO: Vials of AstraZeneca's COVISHIELD, coronavirus disease (Covid-19) vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, India, Nov. 30, 2020. REUTERS/Francis Mascarenhas/File Photo
Coronavirus chronicle

India, 'pharmacy of the world', starts Covid vaccine exports

FILE PHOTO: Vials of AstraZeneca's COVISHIELD, coronavirus disease (Covid-19) vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, India, Nov. 30, 2020. REUTERS/Francis Mascarenhas/File Photo
Coronavirus chronicle

Covishield efficacy higher if gap over 28 days, says India’s Serum Institute

Oxford-AstraZeneca's Covid-19 vaccine. Photo: Reuters.
Covid-19 in Bangladesh

India's Serum to sell AstraZeneca vaccine to Bangladesh at $4/dose

Small bottles labeled with "Vaccine" stickers stand near a medical syringe in front of displayed "Coronavirus Covid-19" words in this illustration taken April 10, 2020/ Reuters
Coronavirus chronicle

India's first shipment of Covid vaccine to land at Delhi airport on Thursday night

Covid-19 vaccines approved by India '110% safe' - DCGI chief
Coronavirus chronicle

Covid-19 vaccines approved by India '110% safe' - DCGI chief

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net